US SB1617 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on May 22 2019 - 25% progression, died in committee
Action: 2019-05-22 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 22 2019 - 25% progression, died in committee
Action: 2019-05-22 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the listing of patents in the Orange Book.
Title
Second Look at Drug Patents Act of 2019
Sponsors
| Sen. Patty Murray [D-WA] | Sen. John Cornyn [R-TX] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-05-22 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
SB4253 (Related) 2020-07-21 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Administrative remedies
Drug safety, medical device, and laboratory regulation
Government information and archives
Health
Intellectual property
Prescription drugs
Drug safety, medical device, and laboratory regulation
Government information and archives
Health
Intellectual property
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/senate-bill/1617/all-info |
| Text | https://www.congress.gov/116/bills/s1617/BILLS-116s1617is.pdf |
